Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Dualyx NV raises €40m in Series A financing
Latest NewsBelgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
Sanofi’s/Astazeneca’s anti-RSV antibody highly effective
Latest NewsNHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
The price of convenient food
BackgroundA UK Biobank analysis of data from 200,000 people over more than ten years,
carried out by British researchers, have linked consumption of ultra-processed foods to an
increased risk of developing and dying from cancer. However, according to the authors from
Imperial College London it doesn’t provide a causal relationship.
Mainz Biomed Partners with Microba Life Sciences
Latest NewsMolecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
DiogenX SA raises €27.5M in Series A financing
Latest NewsFrench pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Immunovia AB with new CEO
AppointmentsJeff Borcherding, President of Immunovia’s US subsidiary since April 2022, has been the new Global CEO of Sweden’s Immunovia AB since the end of April.
Wacker AG expands biotech business through €100m acquisition
Latest NewsMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
BioBLU® Single-Use Bioreactors – Single-Use Simplicity
ProductsSingle-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Changes in the management of Abivax
AppointmentsThe French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
Neogap Therapeutics AB partners with Cellerys AG
Latest NewsSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.